Coherus reports positive data for CCR8+ Treg-depleting antibody

Coherus Oncology (CHRS) announced positive biomarker data from its Phase 1b trial for CHS-114, an anti-CCR8 antibody, demonstrating selective depletion of target cells and enhanced immune activation in head and neck squamous cell carcinoma, particularly when combined with toripalimab. Despite this clinical progress, the company recently missed Q3 2025 earnings and revenue expectations, and analysts project an 82% sales decline for the current year. However, CHRS has maintained profitability over the last twelve months, trades below its fair value, and analysts anticipate significant upside potential from its current $1.49 share price, with targets ranging from $4 to $7.

Analysis

Coherus Oncology (CHRS) reported compelling Phase 1b biomarker data for CHS-114 in HNSCC, demonstrating selective depletion of CCR8+ regulatory T cells by 74% and a 73% increase in CD8+ T cell density. This immune remodeling, evidenced by a 12-fold increase in the CD8+ T cell to CCR8+ Treg ratio, establishes proof of mechanism and supports further development, particularly in combination with toripalimab, where it showed enhanced immune activation and a manageable safety profile.

Despite this clinical progress, the company's recent Q3 2025 financial results fell short of expectations, with EPS of -0.33 USD missing forecasts by 0.01 USD and revenue of 11.6 million USD falling below the anticipated 13.36 million USD. Furthermore, analysts project a significant 82% sales decline for the current year, raising concerns about near-term financial performance, even though the company maintained profitability over the last twelve months.

The stock has experienced recent volatility, dropping 11.3% over the past week, yet it retains an impressive 81.7% return over the last year. InvestingPro analysis suggests CHRS is currently trading below its fair value, and analysts maintain an optimistic outlook with price targets ranging from $4 to $7, indicating substantial upside potential from the current $1.49 share price, driven by the promising clinical pipeline.

Key Decisions for Investors

• Investors should closely monitor upcoming clinical trial milestones for CHS-114, particularly data from combination therapies and expansion arms, as these are critical value drivers.
• Evaluate the company's ability to manage its cash burn and improve revenue generation in light of the Q3 miss and projected sales decline, despite its profitability over the last twelve months.
• Consider the significant discrepancy between the current market valuation and optimistic analyst price targets, weighing the long-term pipeline potential against near-term financial headwinds and recent stock volatility.